Industry Workshops

Industry Workshops provide an opportunity for AMCP corporate members to showcase their latest drug therapies, technologies, and a wealth of products and services affecting professionals working in managed care pharmacy.

All Industry Workshops take place on Tuesday, Oct. 17, from noon–1pm.

What Lies Beneath: The Importance of Earlier Diagnosis and Care of Young Individuals with Duchenne Muscular Dystrophy 

Room: Magnolia 2&3 

Description: In this engaging discussion, experts from Sarepta Therapeutics will review several timely topics related to Duchenne muscular dystrophy: the rationale for prioritizing early diagnosis and intervention, ongoing newborn screening efforts and practices, the magnitude and impact of heterogeneity between patients, and why a one-size fits all approach to tracking patient outcomes is challenging. 

Kathrin Kucharski, PharmD  
Senior Director, Medical Managed Care 
Sarepta Therapeutics  

Erin O’Rourke, MS, CGC  
Senior Director, Medical Affairs Diagnostics 
Sarepta Therapeutics  

Sponsored by Sarepta Therapeutics Inc.

Sarepta Logo

Addressing a Gap in the Treatment of Dry Eye Disease

Room: Magnolia 5&6 

Description: Dry Eye Disease (DED) is very common, but generally undertreated.  There are over 18 million people in the US diagnosed with DED although it’s estimated that as many as 38 million are affected, however, only as few as 1.2 million are being actively treated with a prescription medication.  DED is characterized by 2 main subtypes: Aqueous Deficient and Evaporative.  Inflammation is common in both.  Studies show up to 90% of ALL DED cases have an evaporative component, which represents a treatment gap and unmet need.  MIEBO™ is the first and only prescription eye drop approved by FDA that specifically targets evaporation.   

Jai Parekh, MD, MBA, FAAO 
Co-Founder & CEO 
EyeCare Consultants of NJ  

Sponsored by Bausch+Lomb



VEOZAH (fezolinetant) for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause 

Room: Magnolia 7&8 

Description: In this session, we will review a new, FDA-approved treatment for moderate to severe vasomotor symptoms due to menopause, including indication, mechanism of action, and clinical safety and efficacy. 

Steven McCarus, MD, FACOG 
Chief, Division of Gynecologic Surgery, Advent Health 

Sponsored by Astellas Pharma

Astellas Logo